Abstract:Objective To observe the clinical effects of intravitreal Ranibizumab injection (IVR)for the treatment of the macular edema due to branch retinal vein occlusion.Methods Sixty seven consecutive cases eyes of 67 of the macular edema due to branch retinal vein occlusion treated by IVR (10 mg/ml,0.05 ml) were retrospectively analyzed.All the cases were divided by the following two methods.According to the time between oncome of the macular edema and the first therapy,the patients were divided into 3 groups:group 1 of less than 1 week,group 2 of 1week-3 months and group 3 of over 3 months.And according to the treating regulation,the patients were divided into 2 groups:treatment on time group and treatment on demand group.The follow-up contents included the best corrected visual acuity (BCVA,LogMAR),1 mm diameter macular central retinal thickness (CRT) and fluorescence fundus angiography (FFA).The average follow-up period was (13.2 ± 1.3) months.Results When the group division according to the time between oncome of the macular edema and the first therapy,the BCVA of the patients in group 1 was 0.131 ±0.061 and CRT was (268 ±21) μm two months after the treatment.The BCVA was 0.086 ± 0.042 and CRT was (259 ± 19) μ m 12 months after the treatment.In group 2,the BCVA was 0.276 ± 0.112 and CRT was (321 ± 45) μm 2 months after the treatment and the BCVA was 0.292 ± 0.105 and CRT was (268 ±29) μm 12 months after the treatment.In group 3,the BCVA was 0.523 ±0.164 and CRT was (441 ± 67) μm two months after treatment,and the BCVA was 0.387 ± 0.142 and CRT was (281 ±24) μm 12 months after the treatment.When compared with the group 1,at every follow-up time point,the differences in the BCVAs were statistically significant between group 1 and group 2 (all P ＜0.01).The CRTs at 2,4,6 months after the treatment between group Ⅰ and group 3 had statistically significant differences (all P ＜0.01).When the group division according to the treatment regulation,12months after the treatment,the BCVA was 0.208 ±0.091 in the treatment on time group and was 0.387 ±0.184 in the treatment on demand group and the difference was statistically significant (t =4.35,P ＜0.01).Twelve months after the treatment,the CRT was (290 ±46) μm in the treatment on time group and was (311 ±51) μm in the treatment on demand group,and the difference was not statistically significant(t =0.98,P =0.56).Conclusion The curative effect of IVR for retinal edema due to branch retinal vein occlusion is obvious.Early and on time treatment could significantly improve the effects.

CHOROIDAL BLOOD FLOW AND THICKNESS AS PREDICTORS FOR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION

Effects of Intravitreal Ranibizumab Injection to Treat Macular Edema due to Central Retinal Vein Occlusion on Choroidal Findings and Functional-Morphological Parameters

Baseline Choroidal Blood Flow Imbalance as a Predictive Factor for Macular Edema Recurrence Secondary to Branch Retinal Vein Occlusion

Changes in Macular Microvascular Structure in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Antivascular Endothelial Growth Factor for One Year

CLINICAL FINDINGS OF EYES WITH MACULAR EDEMA ASSOCIATED WITH BRANCH RETINAL VEIN OCCLUSION REFRACTORY TO RANIBIZUMAB

Comparison of Choroidal Thickness, Foveal Avascular Zone, and Macular Capillary Density in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Ranibizumab or Aflibercept—A Prospective Study

Efficacy and Safety of Intravitreal Injection of Ranibizumab in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

Visual Acuity and Retinal Thickness and Sensitivity after Intravitreal Ranibizumab Injection for Macular Edema in Branch Retinal Vein Occlusion

Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema

Clinical Therapeutic Effects of Intravitreal Ranibizumab Injection Combined Laser Photocoagulation for Macular Edema in BRVO

Observation on Intravitreal Injection of Ranibizumab Combined with Laser Photocoagulation for the Treatment of Macular Edema in BRVO

Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion

Anti-VEGF Reduces Inflammatory Features in Macular Edema Secondary to Retinal Vein Occlusion.

Subfoveal Choroidal Thickness and Treatment Outcomes of Intravitreal Aflibercept for Branch Retinal Vein Occlusion

Influence of Aflibercept on Choroidal Blood Flow and Thickness in Branch Retinal Vein Occlusion: A Six-Month Follow-Up Study

Intravitreal Injection of Ranibizumab for the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

Investigation of choroidal structure changes after intravitreal anti-VEGF therapy for retinal vein occlusion

Quantitative Analysis of Retinal Microvascular Changes after Conbercept Therapy in Branch Retinal Vein Occlusion Using Optical Coherence Tomography Angiography

Macular Edema Patterns and Response to Intravitreal Avastin Therapy in Branch Retinal Vein Occlusion

Relationship between Recurrence of Macular Edema Due to Branch Retinal Vein Occlusion and Changes in Choroidal Thickness

Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study